Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ixekizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms IXORA-P
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 23 Sep 2019 Results assessing indirect comparison of long-term efficacy of every-two week versus recommended dosing of ixekizumab by using data from four studies (IXORA P, UNCOVER 1, 2 and 3) published in the British Journal of Dermatology.
  • 10 Sep 2018 According to an Eli Lilly media release, data from this trial will be presented at the 27th annual European Academy of Dermatology and Venereology (EADV) Congress (Sep 2018).
  • 06 Feb 2018 Primary endpoint has been met. (Proportion of Participants Achieving 75% Improvement in Psoriasis Area and Severity Index (PASI 75) in Q2W dose group versus the Q4W dose group) as per results published in British Journal of Dermatology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top